Eisai Co., Ltd. (Tokyo Stock Exchange: 4523) has announced plans to present new five-year clinical follow-up findings for lecanemab, marketed as LEQEMBI, alongside extensive real-world Alzheimer’s disease research at the 19th Clinical Trials on Alzheimer’s Disease Conference in Boston. Announced on October 29, 2026, the programme will include an analysis extending through 60 months of the Clarity AD study, multinational safety research and findings from the LEADER study examining treatment delivery across US clinical settings.
The conference will take place from November 16 to 19, 2026, with Eisai participating in five oral presentations, 19 posters and a dedicated LEADER symposium. The research will address several questions that have become increasingly important since lecanemab received US approval in 2023, including the durability of clinical benefit, the safety of prolonged treatment, the management of amyloid-related imaging abnormalities and the practical consequences of shifting from intravenous infusions towards at-home injections.
However, the October announcement is a presentation preview rather than disclosure of the new five-year results. Eisai has not released the 60-month clinical outcome figures or the complete new real-world safety findings in this announcement. The forthcoming presentations should therefore be distinguished from previously published Clarity AD evidence, which demonstrated that lecanemab slowed average clinical deterioration during the original 18-month randomised study.
Why are the five-year Clarity AD results an important milestone for lecanemab treatment?
Lecanemab is an anti-amyloid beta monoclonal antibody developed by Eisai in collaboration with Biogen Inc. It is designed to bind certain aggregated forms of amyloid beta, including soluble protofibrils, which are implicated in Alzheimer’s disease biology. The treatment aims to reduce amyloid-related pathology and slow clinical deterioration in people with early symptomatic disease.
The pivotal Clarity AD study enrolled 1,795 participants with early Alzheimer’s disease, including individuals with mild cognitive impairment and mild dementia. During the initial 18-month randomised phase, participants received lecanemab or placebo, allowing investigators to compare changes in cognition and daily functioning under controlled conditions. The study established the principal efficacy evidence supporting the medicine’s regulatory development.
At 18 months, the mean change in Clinical Dementia Rating-Sum of Boxes score was 1.21 points in the lecanemab group and 1.66 points with placebo. The adjusted difference of 0.45 points represented approximately 27% less decline on this measure. The result was statistically significant, although both groups experienced worsening and the absolute treatment difference remained modest.
The extension programme is investigating what happens when treatment continues beyond the initial randomised period. Eisai’s scheduled November 16 presentation, identified as abstract OC6, will report initial findings through 60 months. This extends the observation period substantially beyond the evidence available when the medicine first entered routine clinical use.
The importance of the five-year analysis lies in whether clinical and biological effects remain consistent during prolonged treatment. However, the extension’s open-label design introduces limitations that must be considered when interpreting any reported long-term differences. The new data will need to be evaluated in relation to patient retention, treatment exposure and the absence of a continuing randomised placebo comparison.
What can earlier 18-month and 36-month results establish before the new five-year findings are presented?
The original Clarity AD trial demonstrated a statistically significant slowing of clinical decline across several measures, including cognition and daily function. The primary endpoint involved a relatively small difference in average deterioration over 18 months rather than reversal of established dementia. This distinction remains important because treatment benefit should not be confused with restoration of previously lost cognitive abilities.
Longer-term findings from the open-label extension have already been published, including analyses covering up to 36 months of treatment. Researchers reported continued suppression of amyloid plaque levels and findings consistent with sustained clinical benefit across selected cognitive, functional and quality-of-life assessments. The analyses also examined differences between participants who began lecanemab earlier and those who started treatment after the initial placebo period.
According to those published findings, the separation between earlier-start and delayed-start groups was maintained through the 36-month assessment. This supports the hypothesis that initiating treatment earlier may preserve a clinical advantage. However, the extension was not a new randomised comparison of continuous treatment against untreated patients over three years.
That limitation becomes increasingly important as follow-up extends to five years. Participants who remain in long-term studies may differ from those who discontinue because of adverse events, disease progression or other circumstances. Comparisons against projected untreated trajectories can provide useful context but rely on assumptions about how patients would otherwise have progressed.
The forthcoming five-year findings may strengthen confidence in the durability of lecanemab’s effect, particularly if patient numbers, follow-up completeness and analytical methods are clearly reported. However, the existence of a long observation period does not automatically establish increasing benefit or eliminate uncertainty about treatment continuation.
Why does continued lecanemab treatment after amyloid clearance remain a major clinical question?
Lecanemab’s therapeutic mechanism involves reducing amyloid beta pathology, creating an important question about how treatment should be managed after substantial plaque clearance has occurred. If amyloid levels decline sufficiently, clinicians must consider whether continued administration provides additional benefit or whether treatment intensity can safely be reduced. The answer has implications for patients, healthcare costs and the long-term delivery of Alzheimer’s disease care.
Eisai is scheduled to present a poster comparing continuous lecanemab treatment with an alternative finite-treatment strategy associated with donanemab, a different anti-amyloid antibody. The analysis is described as a horizontal matching comparison of long-term clinical trajectories. This indicates an indirect analytical approach rather than a randomised head-to-head clinical trial.
Such comparisons can generate useful hypotheses, but they are limited by differences between the original trials. Patient selection, baseline disease characteristics, dosing schedules and treatment discontinuation rules may differ substantially. Even when statistical techniques attempt to adjust for those differences, unmeasured factors can influence the comparison.
Eisai is also presenting modelled projections examining whether continuous lecanemab treatment could delay progression to moderate Alzheimer’s disease over a 10-year period. These findings will be particularly relevant to long-term treatment planning, but modelled projections are not equivalent to observed outcomes in patients followed for 10 years. Their reliability depends on assumptions about disease progression and treatment effects.
Another poster will examine the durability of biomarker changes after treatment discontinuation. This could help researchers understand whether certain biological effects persist when lecanemab administration stops. However, persistence of a biomarker response does not necessarily establish that clinical benefit remains unchanged.
What will the real-world LEADER study reveal about lecanemab treatment outside controlled clinical trials?
The LEADER study is a multicentre, retrospective investigation examining how lecanemab is being used across diverse clinical settings in the United States. Eisai has scheduled a dedicated symposium on November 18 to present findings covering treatment utilisation, clinical outcomes and the transition from initiation to maintenance therapy. Additional analyses will examine outcomes according to patient sex and experience with at-home subcutaneous administration.
Real-world evidence is important because patients treated in routine practice may differ from those enrolled in controlled trials. Clinical trial eligibility requirements often limit participation according to medical history, disease severity and other factors. Healthcare providers must also manage differences in appointment availability, insurance coverage and access to specialist monitoring.
The LEADER programme could provide useful information about how frequently patients continue treatment and the reasons for modifying or discontinuing therapy. Treatment persistence matters because disease-modifying medicines generally require sustained administration to deliver their intended benefits. However, continued use does not automatically establish that every patient experiences a clinically meaningful improvement.
Retrospective studies also introduce methodological limitations. Patients are not randomly assigned to different treatment strategies, and medical records may differ in completeness across institutions. Associations between treatment patterns and outcomes can be influenced by disease severity, access to care and other factors.
The forthcoming LEADER results will therefore be useful for understanding treatment delivery and generating additional safety information. Their findings should be interpreted alongside the controlled clinical evidence rather than as a replacement for randomised efficacy assessment.
Why are multinational ARIA safety findings important for long-term lecanemab treatment?
Amyloid-related imaging abnormalities, commonly known as ARIA, are an important safety risk associated with anti-amyloid antibody treatment. These abnormalities include ARIA-E, involving swelling or fluid accumulation, and ARIA-H, involving bleeding-related imaging findings such as microhaemorrhages or superficial siderosis. Most events may be asymptomatic, but serious and potentially fatal complications can occur.
The original Clarity AD study reported ARIA-E in approximately 13% of lecanemab-treated participants, compared with approximately 2% receiving placebo. ARIA-H occurred in approximately 17% of treated participants and 9% of placebo recipients. Symptomatic ARIA occurred in approximately 3% of lecanemab-treated patients.
The risk is particularly relevant among individuals carrying certain variants of the APOE gene. Patients who are homozygous for APOE ε4 have a higher incidence of ARIA, including serious events, than heterozygotes or non-carriers. US prescribing information recommends APOE ε4 testing before treatment to inform discussions about risk.
Eisai has scheduled a November 17 presentation examining real-world lecanemab safety and ARIA rates across multiple countries. This analysis could provide additional information about how safety outcomes compare between clinical trials and routine treatment. However, the actual results remain pending, and the announcement does not establish that ARIA rates have decreased in clinical practice.
Multinational comparisons must also account for differences in patient selection, imaging schedules, treatment protocols and adverse-event reporting. A lower reported ARIA rate in one setting could reflect differences in surveillance rather than a genuinely lower biological risk. Detailed methods will therefore be essential for interpreting the forthcoming findings.
How could LEQEMBI IQLIK change the practical delivery of Alzheimer’s disease treatment?
In July 2026, the FDA approved LEQEMBI IQLIK as a subcutaneous starting treatment for early Alzheimer’s disease, expanding an earlier authorisation covering subcutaneous maintenance therapy. The decision allows eligible US patients to receive weekly subcutaneous injections from the beginning of treatment rather than relying exclusively on intravenous infusions during the initial treatment period. The approved starting dose is 500 mg once weekly, administered through two 250 mg autoinjector injections.
Following the initial treatment period of approximately 18 months, eligible patients may transition to an approved maintenance regimen. The subcutaneous maintenance dose is 360 mg once weekly using a single autoinjector. Intravenous dosing remains an alternative under the authorised treatment schedules.
The expanded administration options could reduce some of the time and logistical demands associated with repeated infusion appointments. Patients and care partners may find home administration more convenient, particularly when travelling to specialist centres is difficult. However, the actual benefit will depend on training, patient capability, caregiver support and the requirements of the treatment programme.
At CTAD 2026, Eisai plans to present research concerning patient preference, time savings and real-world experience with subcutaneous administration. These findings could help quantify the practical advantages of the newer delivery system. Nevertheless, the conference announcement does not disclose the study results or establish that all patients prefer injections.
Subcutaneous administration also does not eliminate lecanemab’s ARIA risks or the need for appropriate clinical monitoring. The medicine continues to require careful patient selection and magnetic resonance imaging surveillance according to prescribing requirements. Convenience should therefore be evaluated separately from safety and clinical effectiveness.
What could the alpha-synuclein co-pathology analysis reveal about treatment response?
Alzheimer’s disease is associated principally with amyloid beta and tau pathology, but many patients also have other neurological abnormalities. These can include changes involving alpha-synuclein, a protein associated with Lewy body pathology and certain neurodegenerative disorders. The presence of multiple disease-related processes may influence clinical presentation and progression.
Eisai has scheduled a November 19 oral presentation examining alpha-synuclein co-pathology within the Clarity AD cerebrospinal fluid substudy. The investigation could help clarify how this additional biological characteristic relates to treatment outcomes or other disease markers. However, the announcement does not disclose the specific findings.
Understanding co-pathology may become important as Alzheimer’s treatment becomes increasingly biomarker-driven. Patients with similar amyloid profiles can differ substantially in cognition, neurological symptoms and disease progression. Additional pathological processes may contribute to these differences.
Nevertheless, the presence of alpha-synuclein pathology should not automatically be interpreted as evidence that lecanemab is ineffective or unsuitable for a particular individual. That conclusion would require appropriate clinical evidence. The forthcoming analysis may generate useful information about disease heterogeneity without establishing a new treatment-selection rule.
The broader relevance lies in moving towards a more complete understanding of neurodegeneration. Amyloid reduction addresses one important component of Alzheimer’s disease biology, but it may not directly modify every process contributing to cognitive decline. This creates opportunities for further biomarker research and potential future combination treatment strategies.
What do blood biomarkers and earlier disease detection mean for the future of lecanemab treatment?
Eisai’s CTAD programme includes additional research examining blood-based biomarkers, amyloid and tau measurements, and recruitment for studies involving individuals who have not yet developed noticeable cognitive impairment. These investigations reflect growing interest in identifying Alzheimer’s disease biology at earlier stages. They may eventually influence when disease-modifying treatment can be considered.
Blood tests involving phosphorylated tau, amyloid beta and related measures are being evaluated as tools to support diagnosis and clinical assessment. They may offer practical advantages over more invasive or expensive methods in selected settings. However, the appropriate clinical use of an individual biomarker depends on its validation and intended diagnostic role.
The AHEAD 3-45 research programme is investigating lecanemab in preclinical Alzheimer’s disease, where participants have amyloid-related biological findings but do not meet the same symptomatic criteria as patients in the original Clarity AD trial. Eisai will present analyses concerning screening characteristics and biomarkers within that programme. These research activities do not establish that lecanemab is approved for preventing Alzheimer’s disease in asymptomatic individuals.
The distinction between early symptomatic treatment and prevention is important. The existing US indication specifies that treatment should be initiated in patients with mild cognitive impairment or mild dementia, the stages evaluated in pivotal trials. Extending treatment into asymptomatic populations requires separate evidence demonstrating an acceptable balance between potential benefits and risks.
If future studies establish that earlier treatment produces meaningful clinical advantages, patient identification and access to diagnostic testing could become increasingly important. However, such developments remain dependent on trial outcomes and regulatory review.
How could the CTAD 2026 data influence Eisai’s commercial position and competition with other Alzheimer’s treatments?
Eisai leads global development and regulatory activities for lecanemab in partnership with Biogen. The companies share commercial responsibilities under their collaboration arrangements, making wider treatment adoption relevant to both businesses. The introduction of subcutaneous dosing and expansion into additional markets represent important elements of their commercial strategy.
Competition with other amyloid-directed medicines is an important consideration, particularly with Eli Lilly and Company’s Kisunla, containing donanemab, available in the United States. Differences in treatment schedules, eligibility, safety monitoring and the approach to amyloid clearance can influence clinical decisions. However, separate clinical trials cannot reliably establish the superiority of one medicine over another.
Long-term evidence may influence clinician confidence in maintaining treatment after the initial period. A convincing five-year dataset could strengthen understanding of durability, while real-world findings may clarify practical questions concerning persistence and adverse-event management. Nevertheless, the commercial effect depends on the results actually presented rather than the existence of a long-term follow-up programme.
The LEQEMBI IQLIK approval also creates a potential difference in treatment delivery. Home administration may reduce reliance on infusion centres, but it introduces requirements concerning patient training and safe medication handling. Its value will be determined through real-world experience and patient acceptance.
Payer coverage and the cost of diagnosis, imaging and treatment remain additional considerations. Expanding access to subcutaneous dosing does not automatically remove financial barriers or specialist capacity constraints. The commercial opportunity will depend on the complete care pathway rather than the price or convenience of the medicine alone.
What does Eisai’s share performance indicate ahead of the five-year lecanemab presentations?
Eisai shares closed at ¥5,052 on the Tokyo Stock Exchange on October 30, 2026, increasing 1.57% from the previous session’s ¥4,974. The advance followed a decline of 1.87% on October 29, when the company announced its forthcoming CTAD programme. These movements do not establish a sustained market reaction attributable exclusively to the conference announcement.
Investor interest in lecanemab extends beyond individual clinical presentations because the medicine is an important part of Eisai’s neuroscience strategy. Its potential commercial performance depends on diagnosis rates, treatment initiation, persistence, international access and competition. Additional evidence supporting safe long-term use could influence expectations, but it would need to be evaluated alongside actual commercial uptake.
The five-year Clarity AD presentation is likely to attract particular attention because long-term disease modification remains one of the central questions in Alzheimer’s treatment. However, investors should distinguish observed patient outcomes from comparisons using modelled untreated trajectories. The strength of the evidence will depend on the number of participants followed, retention rates and the methods used to analyse clinical decline.
The real-world LEADER findings may provide a separate indication of how the medicine performs operationally after approval. Treatment persistence and experience with subcutaneous administration could help evaluate the practical sustainability of long-term therapy. Nevertheless, observational findings do not directly establish comparative efficacy.
For Eisai, the November conference offers an opportunity to strengthen the evidence supporting an already commercialised medicine. It is not a regulatory approval event or confirmation of additional revenue, and its financial implications remain uncertain until the findings and subsequent commercial developments become clear.
What will determine whether five-year lecanemab treatment provides a convincing long-term clinical benefit?
The most important evidence will concern the trajectory of cognitive and functional outcomes across the 60-month period. Researchers will need to show how patients changed over time, how many participants remained under observation and how missing data were addressed. The relationship between continued treatment and clinical decline will be more informative than the observation period alone.
Safety will require equally careful assessment. Long-term studies can identify patterns that were not apparent during the original randomised trial, but retention and patient selection may influence the findings. Real-world safety evidence from multiple countries could provide valuable additional information if reporting and monitoring differences are adequately considered.
The appropriate duration of treatment remains another unresolved question. Continued amyloid suppression may be biologically relevant, but the clinical value of maintenance therapy must be evaluated in relation to outcomes, treatment burden and safety. Research comparing continued and finite treatment strategies may inform future decisions, although indirect comparisons cannot replace randomised evidence.
Home administration introduces a further opportunity to improve treatment convenience. However, reducing infusion requirements is not equivalent to reducing all monitoring needs, and patients still require appropriate specialist oversight. The new LEADER findings may clarify how this transition is functioning in practice.
Eisai’s CTAD 2026 programme brings together long-term clinical follow-up, real-world utilisation, safety and emerging biological research. The breadth of the presentations reflects how Alzheimer’s disease treatment has progressed from initial proof of efficacy towards the challenges of sustained delivery and long-term management. The decisive question will be whether the forthcoming evidence strengthens confidence that lecanemab can provide durable, clinically meaningful benefit while maintaining an acceptable safety profile in routine care.
